Inflammation is a shared mechanism in coronary artery disease (CAD) and subsequent heart failure (HF) and circulating monocyte and lymphocyte counts predict CAD severity and outcomes. We investigated whether the monocyte-to-lymphocyte ratio (MLR) correlates with biomarkers of HF and extent of CAD, as well as future HF hospitalizations in patients undergoing coronary angiography (CAG). Therefore, we studied 1754 patients undergoing CAG for stable CAD, unstable angina or myocardial infarction (MI).
Introduction
The role of inflammation and inflammatory cells in cardiovascular disease has been demonstrated in countless studies, showing that leukocyte 1 , monocyte 2 , neutrophil counts 3 and ratios hereof 4 are related to coronary artery disease (CAD) severity and outcome. The monocyte-to-lymphocyte ratio (MLR) has recently been introduced as a potent predictor of mortality among coronary angiography (CAG)
patients. 5, 6 In addition to its role in coronary atherosclerosis, inflammation is also involved in the pathogenesis of heart failure (HF). Although a number of studies have investigated clinical factors 7 and imaging modalities 8 , evidence for the predictive capacity of circulating inflammatory cells in HF prediction is lacking. Given the close relation of higher monocyte levels and lower lymphocyte levels 5 with myocardial injury and subsequent HF, and the strong association of MLR with (cardiovascular 5 ) mortality 6 , we investigated the relation of MLR to HF biomarkers and HF hospitalizations during follow-up among patients with varying degrees of CAD.
Methods
In this study, we included CAG patients from the Utrecht Coronary Biobank (UCORBIO) cohort 9 with available MLR (1754/1845 patients). Indications for CAG were stable CAD (complaints of dyspnea or chest pain upon exertion and >50% stenosis in one of the coronary arteries), unstable angina or MI. Patients undergoing CAG for other indications were excluded from the current analyses.
The medical ethics committee of the UMCU approved the study and all patients provided written informed consent. UCORBIO is registered under the clinicaltrials.gov ID: NCT02304744. The study conforms to the Declaration of Helsinki.
Clinical data were collected as described previously. 10 In brief, demographic data, history of acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), cerebrovascular accident/transient ischemic attack (CVA/TIA) and peripheral arterial disease (PAD), medication use, cardiovascular risk factors: diabetes mellitus, body mass index (BMI), hypertension, hypercholesterolemia, smoking and the indication for CAG, the angiographic severity of CAD and procedural details were collected at the moment of enrollment.
Echocardiographic EF was grouped into 4 categories: <30%, 30-39%, 40-49% and >50%. 4 An arterial blood sample was drawn from the arterial sheath inserted for CAG before any procedurerelated drugs were administered. Differential blood counts were performed in accordance with routine clinical practice using the Abbott Cell-Dyn hematology analyzer. All hematological parameters were subsequently stored in and extracted from the Utrecht Patient-Oriented Database (UPOD).
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Patients are followed-up for 5 years, of which 3 years had passed at the moment of writing.
Every year, patients received a questionnaire to ask for hospital hospitalizations for any reason. When patients reported a potential event or when the patient did not return the questionnaire, the general practitioner or the said hospital was contacted for confirmation of the hospitalization. In case of hospitalization, medical records were requested and a panel of cardiologists adjudicated the event.
All analyses were performed on data with imputed covariates in order to avoid bias caused by data missing-not-completely-at-random. Covariates, but not outcomes (MLR and HF hospitalizations during follow-up) were imputed using multiple imputation ("mice" package for R, m=10 we tested for interaction between indication for angiography and MLR in the analysis for outcome.
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This interaction turned out to be significant and therefore stratified univariable analyses were performed for the indications for CAG. For MLR, we calculated integrated discrimination improvements (IDIs) and continuous net reclassification improvements (cNRIs) as described previously. 6 Because of a positively skewed distribution, MLR, NTproBNP, TnI and hsCRP levels were log-transformed for analysis. All analyses were performed in the Rstudio environment for the R statistical programming software. Tests were two-tailed, a p-value <0.05 was deemed significant. Table 1 summarizes baseline patient characteristics, stratified by low/normal and high MLR.
Results
Unstable angina and MI as compared to stable CAD were related to significantly higher MLR (analyzed as logMLR because of positive skewing) as shown in figure 1A . Univariably, a 1-point increase in logMLR resulted in an odds ratio (OR) of 1. 
Discussion
In CAD patients, MLR was strongly associated with NTproBNP levels and EF. Furthermore, high MLR showed predictive value on top of an extensive clinical risk prediction model for the prediction of HF hospitalizations after CAG. Our data show that MLR is closely related to HF parameters and future HF admissions in CAD patients. This is in line with preclinical studies showing that NFκB P50 in bone marrow-derived cells (and not in cardiomyocytes) determines adverse remodeling independent of infarct size. 12 The current research connects to previous evidence on the predictive value of MLR in cardiovascular disease. In this regard, MLR relates to the severity of CAD 13 and is a predictor of cardiovascular mortality. 5, 6 Moreover, MLR associates with adverse long-7 term outcomes in HF patients. 14 These data indicate that MLR has predictive value not only in atherosclerosis, but also in the prediction of development of de novo HF and of adverse outcome in manifest HF.
Monocytes are key players in atherosclerosis and have been shown to predict cardiovascular and all-cause mortality in cardiovascular disease patients. 5, 15 Monocytes are also involved in adverse remodeling, which may result in HF. 16 However, the role of monocytes is not restricted to detrimental effects. 17 In addition, our data are in line with the previously described relation between lower lymphocyte numbers and poorer functional class in HF patients. 21 The underlying biological with a cell type-specific response to cardiovascular events. Of these, Tregs are of great importance for the modulation and suppression of inflammation, which is key in limiting the development and progression of cardiac damage after various stimuli. 22 This is reflected by the observation that Treg numbers correlate with cardiac function and that both the number and suppressive capacity of Tregs is decreased in HF patients. 23 In addition, several experimental studies have provided mechanistic evidence for the beneficial role of Tregs in hypertrophic remodeling and cardiac dysfunction after pressure-overload hypertrophy 24 and MI. 25 Data on T-cell subsets would therefore be of great interest.
In contrast to T-cells, B-cells compose a small proportion of the total lymphocyte population and have been reported as causal players in atherosclerosis. 26 Conflicting evidence with respect to their relation to cardiac remodeling 27, 28 emphasizes that our understanding of the role of B cells is still in its infancy.
After adjusting for hsCRP levels, MLR remained a significant predictor of future HF hospitalizations, suggesting that MLR provides information beyond systemic inflammation as reflected by hsCRP levels, mediated by IL6. Although hsCRP and IL6 levels are related to CAD severity and prognosis, these associations often disappear after appropriate statistical adjustment. 29 
8
MLR is related to HF markers and HF hospitalizations during follow-up after CAG, independent of NTproBNP. Our results therefore suggest a potential role for MLR alongside or in lieu of NTproBNP. For example, cardiac resynchronization therapy can lower inflammatory markers in plasma. 30 The response of MLR to HF therapy should be investigated as to evaluate its usability in therapy monitoring. The advantages of MLR are the ease of measurement and the low costs of measurement. While NTproBNP costs about €18 in the Netherlands, MLR can be measured for < €2, rendering it a cheap and attractive potential biomarker for risk stratification.
We acknowledge that our findings are limited to one cohort only; validation of our findings in an independent cohort is needed before considering clinical application. Ratios between specific monocyte and lymphocyte subsets, which were unavailable in our study, could further extend our understanding of the relation with HF indicators and improve prediction. Moreover, repeated MLR measurements in time would have been of immense value in order to better understand its role in HF progression. Also, data on the HF biomarkers galectin-3 and ST2 were not available in the current study, hindering direct comparison with MLR.
In conclusion, MLR related significantly to HF markers in CAD patients. Some of these associations remained significant after adjustment for amongst others EF, NTproBNP, TnI and hsCRP levels, suggesting an independent relation. Moreover, MLR had a significant and independent relation with HF hospitalizations during follow-up. 
